Hutchmed says NDA for sovleplenib accepted in China

Hutchmed (HCM) announces that the New Drug Application for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia who have had an insufficient response to at least one previous glucocorticoid treatment has been accepted for review and granted priority review by the China National Medical Products Administration. Sovleplenib is a novel, selective, oral inhibitor targeting spleen tyrosine kinase, being developed for the treatment of immune diseases and hematological malignancies.